Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Preclinical Models Introduction | 8 | 1 |
| GBI Research Report Guidance | 8 | 1 |
| Preclinical Models- Market Overview | 9 | 8 |
| Drug Discovery and Development- An overview | 9 | 1 |
| Drug Discovery | 10 | 1 |
| Preclinical Study/Development | 10 | 1 |
| Clinical Development | 11 | 1 |
| The Phases of a Clinical Trial | 11 | 1 |
| Preclinical Studies- An overview | 12 | 1 |
| Preclinical Study Design and Planning | 12 | 1 |
| Preclinical Study - Strategic Planning | 12 | 1 |
| Key Considerations during Preclinical Study Design | 13 | 1 |
| Establishment of Rationale | 13 | 1 |
| Identification and Selection of a Clinical Indication | 13 | 1 |
| Selection of an Appropriate Species | 13 | 1 |
| Pharmacodynamic and Pharmacokinetic Parameters | 13 | 1 |
| Characterization of Toxicities | 13 | 1 |
| Preclinical Studies- In-house | 14 | 1 |
| Preclinical Studies- Outsourced | 14 | 1 |
| Independent Contracting | 14 | 1 |
| Complete Outsourcing | 14 | 1 |
| Role of a CRO | 15 | 1 |
| Regulatory Aspects of Preclinical Studies | 16 | 1 |
| The Principles of Good Laboratory Practice | 16 | 1 |
| NIH and AAALAC | 16 | 1 |
| Preclinical Models- Preclinical Outsourcing Models | 17 | 10 |
| Reasons for Outsourcing Preclinical Studies | 17 | 1 |
| Optimizing Cost | 18 | 1 |
| Achieving Speed and Flexibility | 18 | 1 |
| Access to Specialty Resources, Technological Advancements, Equipment and Facilities | 18 | 1 |
| Minimizing the Risks Associated with the Early Stages of the Drug Discovery Development Process | 18 | 1 |
| Focus on Core Competencies | 19 | 1 |
| Preclinical Outsourcing Process | 19 | 1 |
| Steps Involved In Outsourcing a Preclinical Project | 19 | 1 |
| Planning and Preparation | 19 | 1 |
| Planning for the Investigational New Drug (IND) Application | 19 | 1 |
| Designing Individual Studies and Preparation of Technical Manuals | 19 | 1 |
| Selection of a CRO | 20 | 1 |
| Legal Agreements | 20 | 1 |
| Criteria for Selecting a Contract Research Organization | 21 | 1 |
| Preclinical Outsourcing Business Models | 22 | 1 |
| Independent Contracting (Functional Business/Service Model) | 22 | 1 |
| Complete Outsourcing (Fully Integrated Business/Service Model) | 23 | 1 |
| Outsourcing Trends | 23 | 1 |
| Strategic Partnerships and R&D collaborations with Pharmaceutical Companies | 23 | 1 |
| Capacity Concerns | 24 | 1 |
| Innovative Management of Outsourcing Projects | 24 | 1 |
| Strategic Shift in Funding and Payment Patterns | 24 | 1 |
| Emergence of One-Stop-Shop CROs and Boutique Providers | 24 | 1 |
| Case Studies | 25 | 1 |
| Early Stage Preclinical Project | 25 | 1 |
| Long Term Partnerships with Drug Discovery and Preclinical Service Providers | 26 | 1 |
| Preclinical Models- Technology Landscape | 27 | 15 |
| Current System | 27 | 1 |
| Overview | 27 | 1 |
| Key Technologies | 27 | 1 |
| Nuclear Magnetic Resonance (NMR) | 27 | 1 |
| X-Ray Crystallography | 28 | 1 |
| Scintillation Proximity Screening Assay | 28 | 1 |
| Radiometric Binding Assay | 28 | 1 |
| Non-Radiometric Assay | 28 | 1 |
| Microfluidics Systems | 28 | 1 |
| In-Vitro ADMET Screening Models | 28 | 1 |
| In-vivo ADMET Screening Models | 29 | 1 |
| Vertebrate Models | 29 | 1 |
| Invertebrate Models | 30 | 1 |
| In-silico ADMET Screening models | 30 | 1 |
| Protein Modeling | 30 | 1 |
| Combinatorial Chemistry Applications | 30 | 1 |
| Data Mining (Data-Based Approach) | 31 | 1 |
| Trends in Technology Models | 31 | 1 |
| Recent Technology Developments | 31 | 1 |
| Biomarkers | 31 | 1 |
| Nanotechnology | 32 | 1 |
| New Approaches | 33 | 1 |
| Genomics, Proteomics and Metabolomics (Omics-technologies) | 33 | 1 |
| Systems Biology/Toxicogenomics Approach | 34 | 1 |
| Surgical Models | 34 | 1 |
| Transgenic Animal Models | 34 | 1 |
| Simulation Models | 34 | 1 |
| Case Studies-Preclinical Models (Technological Developments) | 35 | 1 |
| Apredica s Customized In-vitro ADMET Screening Assays | 35 | 1 |
| AVEO Pharmaceuticals Breakthrough with Transgenic Mouse Model for Human Breast Cancer | 36 | 1 |
| In-vitro Models for Dermal Corrosion / Irritation and Eye Irritation by Charles River | 37 | 1 |
| Preclinical Models of Hepatocellular Carcinoma and Biomarker Strategy by Pfizer | 38 | 1 |
| SimuGen s HT-Stream, a Preclinical Toxicogenomics System/Model | 39 | 1 |
| A Validated Physiologically Based Mathematical Model of Pathogenesis in the Non-Obese Diabetic Mouse by Entelos | 39 | 1 |
| Simulation Modeling to Treat Spinal Cord Injuries by Novartis | 40 | 1 |
| Recent Development in Preclinical Imaging by Caliper Life Sciences | 41 | 1 |
| Preclinical Models- Market Characterization | 42 | 5 |
| Global Spending on Prehuman/Preclinical Studies | 42 | 1 |
| Preclinical Spending by Geography | 43 | 1 |
| Global Preclinical Outsourcing Market | 44 | 1 |
| Key Market Drivers and Restraints | 45 | 1 |
| Market Drivers | 45 | 1 |
| Increasing R&D Expenditure | 45 | 1 |
| Globalization and Outsourcing Advantages in Asian Countries | 45 | 1 |
| Laboratory Animal Supply | 46 | 1 |
| Key Restraints | 46 | 1 |
| Economic Slowdown has Flattened the Demand for Outsourcing Toxicology Studies | 46 | 1 |
| Problems Associated with Recruiting an Experienced Talent Pool | 46 | 1 |
| Preclinical Models- Geographical Analysis | 47 | 10 |
| Germany | 47 | 1 |
| The UK | 48 | 1 |
| Switzerland | 49 | 1 |
| Italy | 50 | 1 |
| France | 51 | 1 |
| Belgium | 52 | 1 |
| Denmark | 53 | 1 |
| Spain | 54 | 1 |
| Sweden | 55 | 1 |
| The US | 56 | 1 |
| Preclinical Models- Company Profiling | 57 | 23 |
| Charles River Laboratories International, Inc. | 57 | 1 |
| Business Overview | 57 | 1 |
| Recent M&A Deals and Strategic Alliances in Preclinical Research | 58 | 1 |
| Charles River Entered a Long-term Licensing Agreement with Transposagen Biopharmaceuticals. | 58 | 1 |
| Charles River Laboratories Acquired Piedmont Research Center | 58 | 1 |
| Charles River Acquired Cerebricon Ltd. | 58 | 1 |
| Charles River Acquired MIR Preclinical Services | 58 | 1 |
| Cyprotex Discovery Ltd. | 59 | 1 |
| Business Overview | 60 | 1 |
| Recent M&A Deals and Strategic Alliances in Preclinical Research | 60 | 1 |
| Cyprotex and TB Alliance Form Collaboration to Accelerate the Discovery of New TB Drugs | 60 | 1 |
| Cyprotex Acquired Apredica LLC | 60 | 1 |
| Shanghai ChemPartner | 61 | 1 |
| Business Overview | 61 | 1 |
| Recent M&A Deals and Strategic Alliances in Preclinical Research | 61 | 1 |
| ChemPartner Entered a Strategic Partnership with Shanghai Clinical Research Center | 61 | 1 |
| Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration | 61 | 1 |
| Covance, Inc. | 62 | 1 |
| Business Overview | 62 | 1 |
| Recent M&A Deals and Alliances in Preclinical Research | 63 | 1 |
| Covance Entered into a Strategic R&D Agreement with Sanofi-Aventis | 63 | 1 |
| Covance Entered into Biomarker Alliance With Rules-Based Medicine, Inc. | 63 | 1 |
| Covance Agreed to Provide Genomic Analysis Services to Merck &Co., Inc. | 63 | 1 |
| Covance Entered into a Multi-Year Marketing Agreement with Phase Forward | 63 | 1 |
| PPD, Inc. | 64 | 1 |
| Business Overview | 64 | 1 |
| Recent M&A Deals and Alliances in Preclinical Research | 64 | 1 |
| PPD Entered into a Collaboration with Lovelace Biomedical and Environmental Research Institute | 64 | 1 |
| PPD Acquired Magen BioSciences | 64 | 1 |
| PPD Enters Into Strategic Collaboration with Merck | 64 | 1 |
| Ricerca Biosciences, LLC | 65 | 1 |
| Business Overview | 65 | 1 |
| Recent M&A Deals and Strategic Alliances | 65 | 1 |
| Ricerca Biosciences Acquired MDS Pharma Services | 65 | 1 |
| Caliper Life Sciences | 66 | 1 |
| Business Overview | 66 | 1 |
| Recent M&A Deals and Strategic Alliances in Preclinical Research | 67 | 1 |
| Caliper Formed a Strategic Collaboration with the Peter MacCallum Cancer Centre | 67 | 1 |
| Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for GPCR Profiling | 67 | 1 |
| Caliper Life Sciences Inc. Formed Alliance with Horizon Discovery | 67 | 1 |
| GVK BIO | 68 | 1 |
| Business Overview | 68 | 1 |
| Recent M&A Deals and Strategic Alliances in Preclinical Research | 69 | 1 |
| GVK BIO and Crelux Collaboratively Set Up Fragment-Based Drug Discovery Platform | 69 | 1 |
| GVK BIO Entered into a Drug Discovery Agreement with Wyeth Pharmaceuticals | 69 | 1 |
| GVK BIO Licensed its Medicinal Chemistry Database (MCD) to GeneGo | 69 | 1 |
| MPI Research | 70 | 1 |
| Business Overview | 70 | 1 |
| Recent M&A Deals and Strategic Alliances in Preclinical Research | 70 | 1 |
| MPI Research Formed a Strategic Collaboration with Kineta | 70 | 1 |
| MDS | 71 | 1 |
| Business Overview | 71 | 1 |
| MD Biosciences | 72 | 1 |
| Business Overview | 72 | 1 |
| Recent M&A Deals and Strategic Alliances in Preclinical Research | 72 | 1 |
| MD Biosciences Formed Collaboration with PharmaGap | 72 | 1 |
| Aptuit | 73 | 1 |
| Business Overview | 73 | 1 |
| Recent M&A Deals and Strategic Alliances in Preclinical Research | 73 | 1 |
| Aptuit Acquires GSK s R&D Operations in Italy | 73 | 1 |
| Aptuit Formed Collaboration with Taiwan Liposome Company (TLC) | 73 | 1 |
| ITR Canada | 74 | 1 |
| Business Overview | 74 | 1 |
| Advinus Therapeutics | 75 | 1 |
| Business Overview | 75 | 1 |
| Recent M&A Deals and Strategic Alliances | 76 | 1 |
| Advinus Established a Collaboration with Ortho-McNeil-Janssen Pharmaceuticals | 76 | 1 |
| Advinus, Genzyme Corporation and Medicines for Malaria Venture (MMV) Establish New Collaboration | 76 | 1 |
| Advinus and DNDi Formed Alliance | 76 | 1 |
| Samaritan Pharma Entered Service Agreement with Advinus Therapeutics. | 76 | 1 |
| Jubilant Biosys | 77 | 1 |
| Business Overview | 77 | 1 |
| Major M&A Deals and Strategic Alliances | 78 | 1 |
| Jubilant Biosys Entered a Co-Marketing Agreement with DiscoveRx | 78 | 1 |
| Jubilant Biosys and Endo Pharmaceuticals formed an R&D Collaboration | 78 | 1 |
| Jubilant Entered Research Collaboration with AstraZeneca | 78 | 1 |
| Jubilant and Orion Established "Hybrid and Integrated " Discovery Collaboration | 78 | 1 |
| Jubilant and BioLeap Formed New Partnership in Drug Discovery | 78 | 1 |
| AMRI | 79 | 1 |
| Business Overview | 79 | 1 |
| Recent Deals in Preclinical Research | 79 | 1 |
| Drug Discovery Research Collaboration with Bristol-Myers Squibb Company | 79 | 1 |
| Preclinical Models- Appendix | 80 | 5 |
| Market Definitions | 80 | 1 |
| List of Abbreviations | 81 | 1 |
| Research Methodology | 82 | 2 |
| Coverage | 82 | 1 |
| Secondary Research | 82 | 1 |
| Primary Research | 83 | 1 |
| Expert Panel Validation | 83 | 1 |
| Contact Us | 83 | 1 |
| Disclaimer | 83 | 1 |
| Sources | 84 | 1 |